INDOAMIN Latest Share Price (INDOAMIN)
TODAY IN ONE LINE
With a market cap of ₹927.67 Cr., it trades at a P/E of 11.47. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
INDOAMIN flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 76.0% YoY
- ●Strong Return on EquityHealthy ROE of 20.1%
- ●Reasonable ValuationTrading at a moderate P/E of 12.6x
- ●High Promoter HoldingPromoters hold 58.4% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 2.0% YoY
- ●Rising Receivables vs SalesReceivables grew 19.5% outpacing sales growth of 14.3%
Latest INDOAMIN News
What changed recently?
Recent events, corporate actions, and announcements.
INDOAMIN valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for INDOAMIN, framed against the sector median so the premium or discount is obvious at a glance.
INDOAMIN trades at a P/E of 11.47× and P/B of 2.37×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
INDOAMIN technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for INDOAMIN — derived from the latest tape, not yesterday's close.
INDOAMIN last traded at ₹137.95 with an intraday range of ₹137.5–₹141.9 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹137.95| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 149.53 | +11.58 | +8.40% |
| R3 | 145.13 | +7.18 | +5.21% |
| R2 | 143.52 | +5.57 | +4.04% |
| R1 | 140.73 | +2.78 | +2.02% |
| PIVOT | 139.12 | 1.17 | 0.85% |
| CURRENT | 137.95 | — | — |
| S1 | 136.33 | -1.62 | -1.17% |
| S2 | 134.72 | -3.23 | -2.34% |
| S3 | 131.93 | -6.02 | -4.36% |
| S4 | 127.53 | -10.42 | -7.55% |
INDOAMIN is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Inside opening range
INDOAMIN financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for INDOAMIN — consolidated or standalone — with margins, YoY growth and key ratios inline.
INDOAMIN reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹927.67 Cr. and reported EPS of ₹4.22.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 1,079 | 1,160 ▲ 7.5% |
| Sales Growth YoY %Derived | 14.31% | 7.51% |
| Other Income | 15 | 29 ▲ 87.6% |
| Total Income | 1,094 | 1,188 ▲ 8.6% |
| 731 | 768 ▲ 5.1% | |
| Gross ProfitDerived | 348 | 391 ▲ 12.6% |
| Gross Margin %Derived | 32.23% | 33.75% |
| 247 | 269 ▲ 8.9% | |
| EBITDA (Operating Profit)Derived | 101 | 123 ▲ 21.5% |
| OPM %Derived | 9.37% | 10.59% |
| 39 | 45 ▲ 15.0% | |
| Profit Before Tax (PBT) | 77 | 106 ▲ 37.9% |
| 21 | 27 ▲ 27.2% | |
| Effective Tax %Derived | 27.36% | 25.24% |
| Total Profit for Period | 56 | 79 ▲ 41.9% |
| Net Profit (Owner's PAT)Derived | 56 | 79 ▲ 41.9% |
| Net Profit Margin %Derived | 5.18% | 6.84% |
| PAT Growth YoY %Derived | 30.56% | 41.92% |
| Earnings Per Share (EPS ₹) | 7.70 | 10.93 ▲ 41.9% |
| Diluted Shares Outstanding (Cr) | 7 | 7 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | -0 | -1 ▼ 4542.7% |
| Total Expenses (incl. D&A & Interest) | 1,017 | 1,082 ▲ 6.4% |
| Material Cost % of RevenueDerived | 67.63% | 66.42% |
| Employee Cost % of RevenueDerived | 5.15% | 5.65% |
| Other Cost % of RevenueDerived | 17.71% | 17.51% |
| Interest Coverage (x)Derived | 3.77x | 4.27x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 489 | 479 ▼ 2.2% | 541 ▲ 12.9% | 786 ▲ 45.4% | 945 ▲ 20.2% | 944 ▼ 0.1% | 1,079 ▲ 14.3% | 1,160 ▲ 7.5% | |
| Sales Growth YoY %Derived | — | -2.16% | 12.91% | 45.42% | 20.22% | -0.14% | 14.31% | 7.51% | |
| Other Income | 7 | 7 ▼ 5.9% | 8 ▲ 22.4% | 10 ▲ 28.5% | 4 ▼ 59.1% | 16 ▲ 281.3% | 15 ▼ 5.7% | 29 ▲ 87.6% | |
| Total Income | 496 | 485 ▼ 2.2% | 549 ▲ 13.0% | 796 ▲ 45.2% | 949 ▲ 19.2% | 960 ▲ 1.1% | 1,094 ▲ 14.0% | 1,188 ▲ 8.6% | |
337 | 321 ▼ 4.9% | 351 ▲ 9.4% | 544 ▲ 55.1% | 655 ▲ 20.4% | 661 ▲ 0.8% | 731 ▲ 10.6% | 768 ▲ 5.1% | ||
| Gross ProfitDerived | 152 | 158 ▲ 3.9% | 190 ▲ 20.0% | 242 ▲ 27.5% | 290 ▲ 19.7% | 283 ▼ 2.3% | 348 ▲ 22.9% | 391 ▲ 12.6% | |
| Gross Margin %Derived | 31.09% | 33.01% | 35.09% | 30.77% | 30.65% | 29.97% | 32.23% | 33.75% | |
98 | 116 ▲ 18.0% | 128 ▲ 10.7% | 190 ▲ 47.8% | 202 ▲ 6.8% | 203 ▲ 0.5% | 247 ▲ 21.2% | 269 ▲ 8.9% | ||
| EBITDA (Operating Profit)Derived | 54 | 42 ▼ 21.9% | 61 ▲ 45.5% | 52 ▼ 14.9% | 87 ▲ 66.8% | 79 ▼ 8.8% | 101 ▲ 27.3% | 123 ▲ 21.5% | |
| OPM %Derived | 11.02% | 8.80% | 11.35% | 6.64% | 9.22% | 8.42% | 9.37% | 10.59% | |
23 | 30 ▲ 31.7% | 20 ▼ 32.8% | 28 ▲ 37.5% | 35 ▲ 23.1% | 38 ▲ 8.5% | 39 ▲ 4.9% | 45 ▲ 15.0% | ||
| Profit Before Tax (PBT) | 38 | 18 ▼ 51.6% | 49 ▲ 167.1% | 35 ▼ 29.5% | 57 ▲ 64.5% | 58 ▲ 2.2% | 77 ▲ 32.5% | 106 ▲ 37.9% | |
13 | 6 ▼ 57.8% | 11 ▲ 107.1% | 11 ▲ 0.2% | 16 ▲ 38.8% | 15 ▼ 4.2% | 21 ▲ 38.1% | 27 ▲ 27.2% | ||
| Effective Tax %Derived | 34.54% | 30.13% | 23.36% | 33.22% | 28.02% | 26.26% | 27.36% | 25.24% | |
| Total Profit for Period | 25 | 13 ▼ 48.3% | 38 ▲ 193.0% | 23 ▼ 38.6% | 41 ▲ 77.3% | 43 ▲ 4.7% | 56 ▲ 30.6% | 79 ▲ 41.9% | |
| Net Profit (Owner's PAT)Derived | 25 | 13 ▼ 48.3% | 38 ▲ 193.0% | 23 ▼ 38.6% | 41 ▲ 77.3% | 43 ▲ 4.7% | 56 ▲ 30.6% | 79 ▲ 41.9% | |
| Net Profit Margin %Derived | 5.07% | 2.68% | 6.95% | 2.93% | 4.33% | 4.54% | 5.18% | 6.84% | |
| PAT Growth YoY %Derived | — | -48.31% | 192.97% | -38.60% | 77.34% | 4.74% | 30.56% | 41.92% | |
| Earnings Per Share (EPS ₹) | 3.72 | 1.92 ▼ 48.4% | 5.31 ▲ 176.6% | 3.26 ▼ 38.6% | 5.78 ▲ 77.3% | 6.06 ▲ 4.8% | 7.70 ▲ 27.1% | 10.93 ▲ 41.9% | |
| Diluted Shares Outstanding (Cr) | 7 | 7 ▲ 0.0% | 7 ▲ 6.0% | 7 ▲ 0.0% | 7 ▲ 0.0% | 7 ▲ 0.0% | 7 ▲ 2.7% | 7 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -0 | -1 ▼ 505.6% | 0 ▲ 136.3% | -0 ▼ 108.1% | 0 ▲ 158.6% | 0 ▲ 69.0% | -0 ▼ 208.7% | -1 ▼ 4542.7% | |
| Total Expenses (incl. D&A & Interest) | 458 | 467 ▲ 1.9% | 500 ▲ 7.0% | 762 ▲ 52.5% | 892 ▲ 17.1% | 902 ▲ 1.0% | 1,017 ▲ 12.8% | 1,082 ▲ 6.4% | |
| Material Cost % of RevenueDerived | 69.68% | 58.19% | 62.05% | 69.35% | 66.87% | 67.93% | 67.63% | 66.42% | |
| Employee Cost % of RevenueDerived | 4.80% | 5.93% | 5.30% | 4.18% | 4.03% | 4.74% | 5.15% | 5.65% | |
| Other Cost % of RevenueDerived | 15.26% | 18.28% | 18.44% | 19.95% | 17.39% | 16.82% | 17.71% | 17.51% | |
| Interest Coverage (x)Derived | 4.37x | 2.08x | 5.44x | 2.73x | 4.05x | 2.88x | 3.77x | 4.27x |
INDOAMIN segment analysis : revenue and profit mix.
Disclosed business segments at INDOAMIN with their share of revenue and profit, switchable between consolidated and standalone reporting.
INDOAMIN discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for INDOAMIN.
Our AI distills the core fundamental drivers supporting INDOAMIN, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
INDOAMIN's investment case rests on 9 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
The company demonstrated strong financial momentum with a significant 49.40% quarter-on-quarter profit growth, reflecting improved operational efficiency and increasing demand for its products.
Indo Amines boasts a healthy Return on Equity (ROE) of 19.00% and Return on Capital Employed (ROCE) of 18.30%, indicating efficient capital utilization and strong profitability.
With a P/E ratio of 14.40, the company appears undervalued compared to the sector P/E of 19.43 and many peers, suggesting potential for re-rating.
The company has shown consistent sales growth, with quarterly sales increasing by 8.55% to 288 Cr, demonstrating a steady expansion in its market reach and product acceptance.
A promoter holding of 58.4% indicates strong confidence from the management in the company's future prospects and long-term stability.
Key Risks.
The company's debt-to-equity ratio stands at 0.90, which is relatively high and could pose a risk during economic downturns or rising interest rate environments.
The current price of 131.00 is significantly below its 52-week high of 211.00, indicating recent stock price volatility and potential investor apprehension.
FII and DII holdings are negligible (0.00-0.16%), suggesting a lack of significant institutional confidence or limited research coverage for the company.
Promoter holding has decreased from 69.33% in 2022 to 58.42% in 2025, which might signal a gradual reduction in insider confidence over time.
The specialty chemicals sector is highly competitive, with larger players like Deepak Nitrite and BASF, posing a threat to market share and pricing power.
Flip Conditions.
Valuation risk. a P/E above 15 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.29. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 15% would indicate weaker capital compounding.
INDOAMIN peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — INDOAMIN is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
INDOAMIN chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for INDOAMIN — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
INDOAMIN delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for INDOAMIN over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in INDOAMIN stood at 63.2% of traded volume, against a 20-day average of 44.5%.
INDOAMIN announcements: results, concalls, ratings, M&A.
Filings INDOAMIN sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
INDOAMIN files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 63 documents below.
Clarification - Financial Results
The Exchange has sought clarification from Indo Amines Limited for the quarter ended 30-Jun-2026 with respect to Regulation 33 of the SEBI (Listing…
Copy of Newspaper Publication
Indo Amines Limited has informed the Exchange about Copy of Newspaper Publication
Shareholders meeting
Indo Amines Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 24, 2026
Record Date
Indo Amines Limited has informed the Exchange that Record date for the purpose of Dividend is 17-Sep-2026.
Copy of Newspaper Publication
Indo Amines Limited has informed the Exchange about Copy of Newspaper Publication
INDOAMIN dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue INDOAMIN has declared, sequenced by announce and record date.
INDOAMIN corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About INDOAMIN: business, sector, key facts.
What INDOAMIN does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
INDOAMIN operates in the Specialty Chemicals industry under the Chemicals sector, listed as NSE: INDOAMIN, BSE: 524648.
INDOAMIN, incorporated in 1992 and headquartered in Thane, India, is a prominent manufacturer, distributor, and seller of fine and specialty chemicals both domestically and internationally. Their extensive product portfolio caters to a diverse range of industries, showcasing their broad capabilities and market reach.
The company's core business revolves around the production of a wide array of fine chemicals. This segment includes various aliphatic and aromatic compounds such as amines, nitriles, halides, alcohols, cycloalkanols, cycloalkanones, acids, and esters. They also manufacture advanced intermediates, amine hydrochlorides, ethanolamines, and other related products. This comprehensive offering underscores their expertise in organic chemistry and their ability to provide building blocks for numerous downstream applications.
Complementing their fine chemical offerings, INDOAMIN also specializes in the production of specialty chemicals. These include a broad spectrum of fatty acids, amides, amines (including di-amines, tertiary amines, and polyamines), amine ethoxylates, and ammonium quats. This signifies their ability to cater to more niche markets demanding specialized chemical compounds with particular properties.
Furthermore, INDOAMIN produces performance chemicals, which are additives designed to enhance the properties of various materials and processes. These include agents such as anticaking, antifoaming, antistatic, antistripping, antibacterial/antislime, and floatation agents. They also provide granulating aids, defoamers, emulsifiers, curing aids, bitumen emulsifiers, corrosion inhibitors, demulsifiers, and antibacterial products. This aspect of their business highlights their contribution to optimizing industrial processes and improving product quality across diverse sectors.
The applications of INDOAMIN's products are incredibly broad, spanning numerous industries. Their chemicals find use in pharmaceuticals, agrochemicals, fertilizers, petrochemicals, perfumery, road construction, pesticides, dyes and intermediates, water treatment, oil field operations, mining, paints and pigments, polymers, metalworking and lubricants, textiles, cosmetics, personal care, printing inks, rubber processing, and surfactants. This diverse range of applications underscores the versatility and importance of their chemical offerings to the global economy.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AARTI INDUSTRIES (AARTIIND) Share PricePeer
- AARTISURF (AARTISURF) Share PricePeer
- ARCHEAN CHEMICAL IND (ACI) Share PricePeer
- AETHER INDUSTRIES (AETHER) Share PricePeer
- ALKALI METALS (ALKALI) Share PricePeer
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
Questions investors ask about INDOAMIN (INDOAMIN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of INDOAMIN (INDOAMIN)?
The current share price of INDOAMIN (INDOAMIN) is ₹137.95. Today, the stock has declined by ₹2.45 (1.75%), trading in a range of ₹137.50 to ₹141.90. The stock opened at ₹141.90 with a trading volume of 1,38,879 shares.
02Is INDOAMIN stock a good investment for long-term?
INDOAMIN can be considered for long-term investment based on several factors. The company has a market capitalization of ₹927.67 Cr., P/E ratio of 11.47, ROE of 20.14%, and ROCE of 13.9%. The dividend yield stands at 0.39%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of INDOAMIN stock?
The 52-week high price of INDOAMIN (INDOAMIN) is ₹149.00, while the 52-week low is ₹81.90. Currently trading at ₹137.95, the stock is 68.44% above its 52-week low and 7.42% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy INDOAMIN stock at the current price?
Whether to buy INDOAMIN stock at ₹137.95 depends on multiple factors. The stock is currently trading with a P/E ratio of 11.47 and P/B ratio of 2.37. Today's performance shows a loss of 1.75%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of INDOAMIN and when is the next dividend?
INDOAMIN offers a dividend yield of 0.39%, which means for every ₹100 invested at the current price of ₹137.95, you can expect to receive approximately ₹0.39 annually as dividends. The face value of the stock is ₹5.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of INDOAMIN?
INDOAMIN's key financial metrics include: P/E Ratio: 11.47, P/B Ratio: 2.37, ROE: 20.14%, ROCE: 13.9%, Dividend Yield: 0.39%, EPS: ₹4.22, Book Value: ₹54.25, and Debt-to-Equity: 0.79. The company's market cap stands at ₹927.67 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is INDOAMIN stock performing today in the market?
INDOAMIN stock opened at ₹141.90 and is currently trading at ₹137.95, showing a decline of ₹2.45 (1.75%). The intraday high is ₹141.90 and low is ₹137.50. The trading volume stands at 1,38,879 shares, indicating moderate market participation today.
08What is the P/E ratio of INDOAMIN and what does it indicate?
INDOAMIN has a Price-to-Earnings (P/E) ratio of 11.47, which means investors are willing to pay 11.47 for every ₹1 of earnings. With an EPS of ₹4.22, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about INDOAMIN (INDOAMIN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.